Dr. Martens (LON:DOCS) Insider Purchases £150.36 in Stock

Dr. Martens plc (LON:DOCS) insider Ije Nwokori acquired 179 shares of the business’s stock in a transaction dated Tuesday, August 11th. The stock was purchased at an average price of GBX 84 per share, for a total transaction of £150.36.

Ije Nwokori also recently made the following trade(s):

• On Thursday, June 25th, Ije Nwokori acquired 118,516 shares of Dr. Martens stock. The stock was purchased at an average cost of GBX 72 per share, for a total transaction of £85,331.52.
• On Thursday, June 11th, Ije Nwokori bought 202 shares of Dr. Martens stock. The shares were acquired at an average cost of GBX 74 per share, with a total value of £149.48.
• On Friday, June 12th, Ije Nwokori purchased 112,500 shares of Dr. Martens stock. The stock was acquired at an average price of GBX 76 per share, for a total transaction of £85,500.

Dr. Martens Trading Down 0.5%

Shares of DOCS stock opened at GBX 88.07 on Friday. The company has a quick ratio of 1.13, a current ratio of 2.61 and a debt-to-equity ratio of 108.85. Dr. Martens plc has a fifty-two week low of GBX 59.15 and a fifty-two week high of GBX 100.87. The firm’s 50 day moving average price is GBX 75.19 and its two-hundred day moving average price is GBX 69.41. The stock has a market cap of £842.94 million, a price-to-earnings ratio of 36.70, a price-to-earnings-growth ratio of 6.40 and a beta of 0.26.

Dr. Martens (LON:DOCS) last released its quarterly earnings data on Tuesday, May 19th. The company reported GBX 4.20 earnings per share (EPS) for the quarter. Dr. Martens had a net margin of 3.11% and a return on equity of 6.89%. The company had revenue of £764.90 million during the quarter. On average, analysts anticipate that Dr. Martens plc will post 2.5809394 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on DOCS shares. Royal Bank Of Canada reiterated a “sector perform” rating and issued a GBX 100 target price on shares of Dr. Martens in a research note on Tuesday, June 2nd. Berenberg Bank lowered their price objective on shares of Dr. Martens from GBX 114 to GBX 110 and set a “buy” rating for the company in a research report on Tuesday, May 19th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, Dr. Martens currently has a consensus rating of “Moderate Buy” and an average price target of GBX 105.

About Dr. Martens

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.